|
|
 = Add Release to Briefcase |
| All Releases |
|---|
 |
Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
05/29/09
|
14.8 KB
|
| |
CORAL GABLES, Fla., May 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced top-line results from its U.S. Phase II clinical trial to treat cocaine addiction. The data from the trial showed that CPP-109 did not demonstrate statistical significance in the primary endpoint ...
|
|
|
Catalyst Pharmaceutical Partners Receives NASDAQ Deficiency Notice
05/22/09
|
13.0 KB
|
| |
CORAL GABLES, Fla., May 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced that on May 19, 2009 it was advised by The NASDAQ Stock Market(R) that, based on the Company's stockholders equity as reported in the Company's Quarterly Report on Form 10-Q for the quarter ended M...
|
|
|
Catalyst Pharmaceutical Partners Reports First Quarter 2009 Financial Results
05/14/09
|
15.9 KB
|
| |
CORAL GABLES, Fla., May 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today reported financial results for the first quarter ended March 31, 2009.
First Quarter 2009 Results
For the quarter ended March 31, 2009, the Company reported a net loss of $3,031,201, or $0.22 per basic and...
|
|
|
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
03/27/09
|
17.4 KB
|
| |
CORAL GABLES, Fla., March 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today reported financial results for the fourth quarter and year ended...
|
|
|
Catalyst to Focus Resources on its Lead Indication for CPP-109; Cocaine Addiction
03/03/09
|
13.7 KB
|
| |
CORAL GABLES, Fla., March 3, 2009 /PRNewswire via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today announced modifications to its previously announced product development p...
|
|
|
Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial
01/09/09
|
14.2 KB
|
| |
CORAL GABLES, Fla., Jan 09, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst
Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that
acquires, in-licenses, develops and commercializes prescription drugs for the
treatment of drug addiction, announced today that it has reached its patient
enrollment target in...
|
|
|
Catalyst Pharmaceutical Partners Reports Third Quarter 2008 Financial Results
11/14/08
|
16.5 KB
|
| |
CORAL GABLES, Fla., Nov 14, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today reported financial results for the third quarter and nine months ended September 30, 2008.
"The 2008 third quarter was marked by continued strong execution and progress in our clinical development progra...
|
|
|
Catalyst Pharmaceutical Partners to Present at the Rodman & Renshaw 10th Annual Global Investment Conference
11/03/08
|
12.2 KB
|
| |
CORAL GABLES, Fla., Nov 03, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) a biopharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction and obsessive compulsive disorders, today announced that Patrick J. McEn...
|
|
|
Catalyst Pharmaceutical Partners, Inc. Announces a $4.5 Million Registered Direct Common Stock Offering
09/12/08
|
14.5 KB
|
| |
CORAL GABLES, Fla., Sept 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction and obsessive compulsive disorders, today announced that it has entered ...
|
|
|
Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
08/21/08
|
14.4 KB
|
| |
CORAL GABLES, Fla., Aug 21, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today reported that animal data from a new study sponsored by scientists at the U.S. Department of Energy's Brookhaven National Laboratory appears to demonstrate that taking vigabatrin leads to rapid weight loss a...
|
|
|
Catalyst Pharmaceutical Partners Reports Second Quarter 2008 Financial Results
08/15/08
|
16.1 KB
|
| |
CORAL GABLES, Fla., Aug 15, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today reported financial results for the second quarter and six months ended June 30, 2008.
"We continue to progress with our clinical development program for CPP-109," stated Patrick J. McEnany, Catalyst's Ch...
|
|
|
Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
06/30/08
|
16.2 KB
|
| |
CORAL GABLES, Fla., June 30, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction and obsessive compulsive disorders, today announced that it has begun ...
|
|
|
Catalyst Pharmaceutical Partners, Inc. Set to Join Russell Microcap® Index
06/25/08
|
13.7 KB
|
| |
CORAL GABLES, Fla., June 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced today that it is set to join the Russell Microcap® Index when Russell Investments reconstitutes its family of U.S. indexes on June 27, 2008, according to a prelimin...
|
|
|
Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement
06/03/08
|
12.4 KB
|
| |
CORAL GABLES, Fla., June 3, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction and obsessive compulsive disorders, today announced the filing of a shelf...
|
|
|
Catalyst Pharmaceutical Partners Reports First Quarter 2008 Financial Results
05/16/08
|
17.5 KB
|
| |
CORAL GABLES, Fla., May 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today reported financial results for the quarter ended March 31, 2008. The Company also announced the addition of Frank Greenway, M.D. to Catalyst's Scientific Advisory Board and the retention of Andrew Forman as ...
|
|
|
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
03/26/08
|
17.9 KB
|
| |
CORAL GABLES, Fla., March 26, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today reported financial results for the fourth quarter and year ended...
|
|
|
Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance
03/05/08
|
14.0 KB
|
| |
CORAL GABLES, Fla., March 5, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today announced the appointment of Patrick Kenny as Director - Corporate Clinical Compliance. In this capacity, Mr. Kenny will be responsible for ensuring the effectiveness and GCP compliance of the CROs, clinica...
|
|
|
Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
01/25/08
|
15.2 KB
|
| |
CORAL GABLES, Fla., Jan 25, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today announced that it has initiated enrollment of patients for its 180...
|
|
|
Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction
12/07/07
|
15.9 KB
|
| |
CORAL GABLES, Fla., Dec 07, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today announced positive initial top-line results from an investigator-i...
|
|
|
Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results
11/14/07
|
15.3 KB
|
| |
CORAL GABLES, Fla., Nov 14, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) today reported financial results for the quarter ended September 30, 2007.
Third Quarter 2007 Results
For the quarter ended September 30, 2007, the Company reported a net loss of $734,347 o...
|
|
|
|
Stock Information
| CPRX |
NASDAQ |
| Price: |
$0.62 |
| Change: |
- 0.02
|
| 07/02/09 2:58 PM ET |
Data delayed at least 20 min.
Information provided by eSignal.
|
